

Filed 1/27/05

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031



U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: January 24, 2005 (use as many sheets as necessary)				Complete if Known	
				Application Number	10/089,362
				371(c) Filing Date	1/14/2003
				First Named Inventor	David Elsley
				Group Art Unit	1616
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	355908-2650
Sheet	1	of	1		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
	C1	Athyros et al. "Safety and Efficacy of Long-term Statin-Fibrate Combinations in Patients with Refractory Familial Combined Hyperlipidemia" <i>Am. J. Cardiol.</i> 80:608-613 (1997)		
	C2	Tikkanen, Matti J. "Statins: within-group comparisons, statin escape and combination therapy" <i>Current Opinion in Lipidology</i> 7:385-388 (1996)		
	C3	Orehov et al. "Antiatherosclerotic and antiatherogeni effects of a calcium antagonist plus statin combination: amlodipine and lovastatin" <i>Int. J. Cardiol. (Suppl. 2):S67-S77</i> (1997)		
	C4	Kostner, K.M. "Aggressive Therapie und Kombinationstherapie bie schweren Hyperlipidämien" <i>WMW-5/6/1999 Themenheft: "HMG-CoA-Reduktase-Hemmer"</i> 1-3		N
	C5	Feher et al. "Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease" <i>Br. Heart J.</i> 74:14-17 (1995)		
	C6	Orehov et al. "Anti-Atherogenic Effect of Calcium Antagonist Plus Statin Combination" <i>Cardiovascular Drugs and Therapy, Kluwer academic Publishers, Boston, U.S.</i> Vol. 11, no. 2:350 (1997)		

Examiner Signature	Date Considered	12/29/05
--------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.